Strides Arcolab posts Rs 260-crore revenue in Q1 FY 2014-15 EBITDA growth of 34 per cent over Q2 FY’14

Strides Arcolab has posted its financial results for the quarter ending June 30, 2014. The consolidated pharma revenues is at Rs 260 crores vs Rs 229 crores in Q2 FY’14, showing a growth of 14 per cent. The consolidated pharma EBITDA is at Rs 54 crores vs Rs 41 crores in Q2 FY’14, growth of 34 per cent.

EBITDA margin is at 21 per cent vs. 18 per cent in Q2 FY’14. The EBITDA Margin improvement has been driven by newer launches in regulated markets and margin expansion in brands business. Delays in malarial contract finalisation impacted institutional business.

In regulated markets, the revenue has been reported at Rs 109 crores, representing 42 per cent of the total revenues. In institutional business category, revenue has been reported at Rs 73 crores, representing 28 per cent of the total revenues. In emerging markets, revenue is at Rs 78 crores, representing 30 per cent of the total revenues.

Commenting on the results, Arun Kumar, Founder and Group Chief Executive Officer, stated, “We had a very consistent performance over the last few quarters, with improved margins across all segments. With the flow of product approvals from US FDA and acceleration in the branded generics through acquisition of ‘Raricap’, we see significant traction in the business.”

EP News Bureau- Mumbai